Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACYCLOVIR vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acyclovir is a synthetic nucleoside analog that inhibits viral DNA replication. It is phosphorylated to acyclovir monophosphate by viral thymidine kinase, then converted to acyclovir triphosphate by cellular kinases. Acyclovir triphosphate competes with deoxyguanosine triphosphate for viral DNA polymerase, incorporating into viral DNA and causing chain termination.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Herpes simplex virus (HSV) infections: genital herpes, herpes labialis, herpes simplex encephalitis, neonatal herpes,Varicella-zoster virus (VZV) infections: chickenpox, herpes zoster (shingles),Mucocutaneous HSV infections in immunocompromised patients,Prophylaxis of HSV and VZV infections in immunocompromised patients
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
400 mg orally twice daily for herpes zoster; 200 mg orally 5 times daily for genital herpes; 5-10 mg/kg intravenously every 8 hours for severe infections.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life is 2.5–3.3 hours in adults with normal renal function; increases to 19.5 hours in anuria.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Acyclovir is partially metabolized by alcohol and aldehyde dehydrogenase. The major metabolite is 9-carboxymethoxymethylguanine (CMMG), which is inactive. Hepatic metabolism is minimal, and the drug is predominantly excreted unchanged in urine via glomerular filtration and tubular secretion.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 62-90% of elimination. Fecal elimination is <2%.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
9–33% bound to plasma proteins (albumin).
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Vd: 0.5–1.5 L/kg. Distributes widely; crosses blood-brain barrier achieving 50% of plasma CSF concentration.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: 15–30% (dose-dependent). Topical: Minimal systemic absorption (<5%).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Cr Cl >25 m L/min: no adjustment; Cr Cl 10-25 m L/min: standard dose every 12 hours; Cr Cl <10 m L/min: standard dose every 24 hours.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No dose adjustment required for hepatic impairment; no Child-Pugh based modifications established.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Neonates: 10-20 mg/kg intravenously every 8 hours; Children: 250-600 mg/m² orally 3-5 times daily or 5-10 mg/kg intravenously every 8 hours.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Adjust based on renal function; start at low end of dosing range; monitor for neurotoxicity.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None. Acyclovir does not have a black box warning.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Renal impairment: Dose adjustment required for Cr Cl < 50 m L/min; risk of acute renal failure due to crystallization in renal tubules, especially with rapid IV infusion or dehydration,Neurologic toxicity: Elderly patients or those with renal impairment may develop CNS effects (agitation, hallucinations, seizures); use with caution,Hematologic: Rare reports of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) in immunocompromised patients,IV administration: Avoid rapid infusion, ensure adequate hydration to prevent renal damage
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to acyclovir or valacyclovir,Lactation: Caution advised; excreted in breast milk
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No significant food interactions. High-fat meals may reduce absorption but not clinically significant. Avoid excessive alcohol as it may worsen side effects (e.g., dizziness).
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Acyclovir is generally considered low risk during pregnancy. Data from the Acyclovir Pregnancy Registry and postmarketing studies do not show an increased risk of major birth defects compared to the general population. However, high-dose IV acyclovir in first trimester for severe infections carries theoretical risk; use only if clearly needed. No known specific fetal risks by trimester beyond those of the underlying infection.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Acyclovir is excreted into breast milk with a milk-to-plasma ratio (M/P) of approximately 0.6 to 4.1. An exclusively breastfed infant would receive 0.1-1% of maternal dose (or 0.3-0.7 mg/kg/day based on typical maternal 200 mg oral dose), which is below neonatal therapeutic doses. American Academy of Pediatrics considers acyclovir compatible with breastfeeding. Monitor infant for rash or gastrointestinal disturbance.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Pregnancy does not significantly alter acyclovir pharmacokinetics; no dose adjustment needed for oral or IV acyclovir. Standard dosing regimens for HSV (e.g., 200-400 mg PO TID for genital herpes or 5-10 mg/kg IV q8h for severe infection) are used. In third trimester, increased renal clearance may require slightly higher doses for VZV (typically 800 mg PO 5 times/day), but no formal recommendations for dose increase. Always adjust for renal impairment separately.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Acyclovir requires adequate hydration to prevent crystalluria and nephrotoxicity; ensure urine output >500 m L/q8h. For IV acyclovir, infuse over at least 1 hour to avoid renal damage. Dose adjustment required in renal impairment (Cr Cl <50 m L/min). Early initiation (within 72 hours of rash) improves outcomes in herpes zoster. Oral acyclovir has low bioavailability (15-30%); valacyclovir is a prodrug with better absorption.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take acyclovir exactly as prescribed, even if symptoms improve.,Drink plenty of water during treatment to prevent kidney problems.,Start medication at the first sign of outbreak for best results.,Do not share your medication with others.,Avoid sexual contact when lesions are present to prevent transmission.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACYCLOVIR vs ABSTRAL, answered by our medical review team.
ACYCLOVIR is a Antiviral that works by Acyclovir is a synthetic nucleoside analog that inhibits viral DNA replication. It is phosphorylated to acyclovir monophosphate by viral thymidine kinase, then converted to acyclovir triphosphate by cellular kinases. Acyclovir triphosphate competes with deoxyguanosine triphosphate for viral DNA polymerase, incorporating into viral DNA and causing chain termination.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACYCLOVIR and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACYCLOVIR is: 400 mg orally twice daily for herpes zoster; 200 mg orally 5 times daily for genital herpes; 5-10 mg/kg intravenously every 8 hours for severe infections.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACYCLOVIR and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACYCLOVIR is classified as Category A/B. Acyclovir is generally considered low risk during pregnancy. Data from the Acyclovir Pregnancy Registry and postmarketing studies do not show an increased risk of major birth defec. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.